Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27107103 | 0.86 | USP1 (0.33) | ACVR1BRD4CREBBP | |
| SCHEMBL29766738 | 0.86 | HDAC1 (0.32) | ACVR1BRD4CREBBP | |
| SCHEMBL25897441 | 0.86 | HDAC1 (0.32) | ACVR1BRD4CREBBP | |
| SCHEMBL25897385 | 0.79 | DRD4 (0.47) | — | |
| SCHEMBL25426200 | 0.76 | ADRA2A (0.30) | — | |
| SCHEMBL29766606 | 0.76 | ADRA2A (0.30) | — | |
| SCHEMBL29766648 | 0.75 | IDO1 (0.35) | — | |
| SCHEMBL25900011 | 0.75 | IDO1 (0.35) | — | |
| SCHEMBL25897621 | 0.70 | DGAT1 (0.32) | — | |
| SCHEMBL25897386 | 0.68 | PBRM1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242546-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | SUDO BIOSCIENCES LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| US-20230242546-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | SUDO BIOSCIENCES LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242546-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | TYK2, PDXK, JAK1 | ACVR1 2211/4885BRD4 73/4885CREBBP 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.